Evaxion Biotech A/S (NASDAQ:EVAX) Sees Significant Increase in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 86,700 shares, a growth of 48.0% from the February 13th total of 58,600 shares. Currently, 8.2% of the company’s stock are sold short. Based on an average daily trading volume, of 2,250,000 shares, the short-interest ratio is presently 0.0 days.

Evaxion Biotech A/S Stock Performance

Shares of NASDAQ:EVAX traded down $0.01 during midday trading on Friday, reaching $1.78. 44,601 shares of the company’s stock traded hands, compared to its average volume of 595,249. Evaxion Biotech A/S has a one year low of $1.70 and a one year high of $22.05. The stock has a 50 day moving average of $2.86 and a 200 day moving average of $8.23. The company has a market cap of $2.09 million, a price-to-earnings ratio of -1.23 and a beta of -0.25. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S as of its most recent filing with the Securities & Exchange Commission. 11.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on EVAX shares. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a report on Thursday, February 20th. Lake Street Capital cut their price objective on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.